The centre aims to accelerate innovations in oncology for all patients in the Hauts-de-France region.
It represents the first location in the region of Lille to provide advanced MRI-guided radiation therapy.
Through diagnostic-quality MR images, ViewRay’s MRIdian system offers better anatomical visualisation to clinicians, as well as the ability to improve targeting precision and provide effective radiation doses.
The combination of the latest innovations in precision radiation therapy, advanced MR image guidance and on-table adaptive therapy will allow physicians to define tight treatment margins and avoid unnecessary radiation exposure for healthy tissue, in addition to at-risk organs.
It also allows ablative radiation doses to be provided in five or fewer treatment sessions, without depending on implanted markers.
MRIdian provides real-time continuous tracking of the target and at-risk organs, allowing automatic gating of the radiation beam if the target moves outside the user-defined margins.
This allows prescribed dose delivery to the target while surrounding healthy tissue and critical structures are avoided.
It will also reduce the toxicities that are associated with conventional radiation therapy.
ViewRay chief medical officer Martin Fuss said: “With MRIdian, Centre Oscar Lambret will offer personalised treatment to a broader population of cancer patients.
“Through the use of MRI-guidance, on-table adaptive replanning capabilities, and the ability to control the radiation beam based on real-time MR-imaging during treatment, Centre Oscar Lambret will improve the accuracy with which they deliver radiation treatments.
“Patients will benefit from higher radiation doses delivered in fewer treatment sessions, even if they may have tumours that are today considered virtually untreatable.”
Centre Oscar Lambret intends to start treating patients in early 2024.
53 MRIdian radiation therapy systems are currently installed at hospitals worldwide.